Recombinant human insulin is the synthetic insulin, developed using recombinant DNA technology by growing insulin proteins within Escherichia coli. Recombinant human insulin has a faster onset of action and lower immunogenicity than other types of insulin such as pork or beef insulin. Human insulin is available primarily in two forms: a short acting (regular) form and an intermediate acting (NPH) form. Moreover, the premixed human insulin is formed by combining two types of insulin, among which one is controls blood sugar level throughout the day, while second type of insulin helps to control blood sugar at meal times. Human recombinant insulin market is gaining traction due to development of biosimilar analogue of insulin, worldwide.
Grab Sample of this Report at: @
Market Dynamics
Sedentary and unhealthy lifestyle, binge eating, obesity, impaired glucose tolerance, diabetes family history, and increased insulin resistance are some of the risk factors for developing diabetes among the global population. Moreover, increasing number of diabetic population, and growing research and development (R&D) studies in human recombinant insulin to introduce improved version of insulin in the market is expected to boost the growth of human recombinant insulin market in near future. Key manufactures are launching innovative and improved human recombinant insulin in the market to fulfill the increasing demand for insulin. According to the Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS): 2016 report, global insulin market is largely dominated by three pharmaceutical companies: Novo Nordisk A/S, Sanofi S.A. and Eli Lilly and Company. Furthermore, Southeast Asia and Latin America accounts with higher number of smaller human recombinant insulin manufactures, than other regions.
Key features of the study:
• This report provides in-depth analysis of human recombinant insulin in pharmaceutical sector and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global human recombinant insulin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
• Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Dongbao Enterprise Group Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion and marketing tactics
• The global human recombinant insulin market report caters to various stakeholders in this industry including investors, suppliers, human recombinant insulin manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the human recombinant insulin market.
Detailed Segmentation:
• Global Human Recombinant Insulin Market, By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
• Global Human Recombinant Insulin Market, By Brand:
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
• Global Human Recombinant Insulin Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Human Recombinant Insulin Market, By Region:
o North America
o By Country:
o U.S.
o Canada
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Europe
o By Country:
o Germany
o France
o Italy
o UK
o Spain
o Russia
o Rest of Europe
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Asia Pacific
o By Country:
o China
o India
o Japan
o South Korea
o Australia
o Rest of Asia Pacific
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Middle East
o By Country:
o GCC
o Israel
o Rest of Middle East
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Latin America
o By Country:
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Africa
o By Country:
o South Africa
o Central Africa
o North Africa
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Company Profiles
o Novo Nordisk A/S *
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments
o Strategies
o Eli Lilly and Company
o Sanofi S.A.
o Julphar Gulf Pharmaceutical Industries
o Biocon Limited
o Bioton S.A.
o Gan & Lee Pharmaceuticals, Ltd.
o Zhuhai United Laboratories Co., Ltd.
o Wanbang Biopharmaceuticals Co., Ltd.
o Dongbao Enterprise Group Co., Ltd.
Get Exclusive Discount at: @
“*” marked represents similar segmentation in other categories in the respective section.
Industry Forecast Research 